{
  "name": "Xbrane Biopharma",
  "slug": "xbrane-biopharma",
  "description": "Statiskt källarkiv med kurshistorik, finansiella rapporter och regulatoriska dokument. För nordiska bolag används Nasdaq Nordic primärt och MFN endast för saknade rapportperioder.",
  "status": "complete",
  "updated_at": "2026-08-07T08:44:50Z",
  "nasdaq_status": "retrieved",
  "latest_market": "2026-08-06: stängning 10.10, volym 2686",
  "mfn_status": "resolved_no_reports",
  "mfn_count": 0,
  "nasdaq_reports_status": "retrieved",
  "reports": {
    "available": true,
    "url": "/company/xbrane-biopharma/reports",
    "count": 17,
    "nasdaq_count": 17,
    "mfn_fallback_count": 0,
    "items": [
      {
        "report_key": "2026:q2",
        "period_label": "2026 Q2",
        "date": "2026-07-17",
        "title": "Kvartalsrapport Q2 2026",
        "original_title": "Xbrane Biopharma publicerar Delårsrapport januari-juni 2026",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bf047b993615d2f514f24206cf1fed5fd&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2026,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2026",
            "title": "Kvartalsrapport Q2 2026",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a8b00b947a5558a7cef2b0564a7b70cac",
            "date": "2026-07-17",
            "period": "2026-q2",
            "form_type": "interim-report",
            "report_key": "2026:q2",
            "filename": "Xbrane_Q2_2026_SVE_Final.pdf",
            "text_chars": 51755,
            "sha256": "7e3d3748b4c0f10fcbf22c4cb67faf9669e1483be41ef2ce36e7b6f44414b2d3",
            "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026",
            "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026",
            "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026/part-001.html",
                "chars": 51755
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2026:q1",
        "period_label": "2026 Q1",
        "date": "2026-05-05",
        "title": "Kvartalsrapport Q1 2026",
        "original_title": "Xbrane Biopharma ABs (publ.) (”Xbrane”) delårsrapport för januari-mars 2026 finns från och med idag tillgänglig på bolagets webbsida, www.xbrane.com.",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b230a0183c7f5a68913d1d3421a036d3d&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2026,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
            "title": "Kvartalsrapport Q1 2026",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/acc297eb055190ad3b4286e211b143166",
            "date": "2026-05-05",
            "period": "2026-q1",
            "form_type": "interim-report",
            "report_key": "2026:q1",
            "filename": "Xbrnane_Q1_2026_SVE_Final.pdf",
            "text_chars": 45705,
            "sha256": "357f9101e71e4b40226b094761e2e48c3bf75479d1e9ee875639dd80adf3ccf2",
            "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
            "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
            "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
                "chars": 45705
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:annual",
        "period_label": "2025 Årsredovisning",
        "date": "2026-03-31",
        "title": "Årsredovisning 2025",
        "original_title": "Xbrane har publicerat års- och hållbarhetsredovisningen för 2025. Redovisningen sammanfattar affärsverksamhet, finansiellt resultat samt hållbarhetsarbetet.",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=ba8507658bec6911c1b60778bf56679cf&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2025,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2025",
            "title": "Årsredovisning 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a9d342a40ad1e12dc500324a338e7209f",
            "date": "2026-03-31",
            "period": "2025-annual",
            "form_type": "annual-report",
            "report_key": "2025:annual",
            "filename": "Xbrane_AR_2025.pdf",
            "text_chars": 343429,
            "sha256": "fa1e0f6252dbc314c29334cc9f47339e138eda9fe1bbb323c6b6604635fdec75",
            "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2025",
            "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2025",
            "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
                "chars": 174293
              },
              {
                "number": 2,
                "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
                "chars": 169134
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q4",
        "period_label": "2025 Q4",
        "date": "2026-02-20",
        "title": "Kvartalsrapport Q4 2025",
        "original_title": "Xbrane Biopharma publicerar bokslutskommuniké 2025",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b4a47b654ab5d44680744f0808f9851fe&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2025,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
            "title": "Kvartalsrapport Q4 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a813f72aa1fe1d92f6a7849f53ce18fb2",
            "date": "2026-02-20",
            "period": "2025-q4",
            "form_type": "year-end-report",
            "report_key": "2025:q4",
            "filename": "Xbrane_Q4_2025_SV_Final.pdf",
            "text_chars": 52117,
            "sha256": "ccb9f087648165009e342257f1663f96082a2f50d5602cc0c5b9c88137520dd3",
            "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
            "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
            "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
                "chars": 52117
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q3",
        "period_label": "2025 Q3",
        "date": "2025-10-24",
        "title": "Kvartalsrapport Q3 2025",
        "original_title": "Xbrane Biopharma publicerar Delårsrapport januari-September 2025",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b5f3e1a4e564123e3b09c684175fef78e&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
            "title": "Kvartalsrapport Q3 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ae3a7879bcb3b8d96fb5b9d491e2691eb",
            "date": "2025-10-24",
            "period": "2025-q3",
            "form_type": "interim-report",
            "report_key": "2025:q3",
            "filename": "Xbrane_Biopharma_Publicerar_Delarsrapport_Januari_September_2025.pdf",
            "text_chars": 53374,
            "sha256": "088aab35dd2d493f1f1dd6900780ae3ccef45d7ecea2df6a44e3e6f956d86223",
            "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
            "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
            "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
                "chars": 53374
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q2",
        "period_label": "2025 Q2",
        "date": "2025-08-26",
        "title": "Kvartalsrapport Q2 2025",
        "original_title": "Xbrane Biopharma publicerar Delårsrapport januari-juni 2025",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=ba1ae222d47a4a58091d420b7012f4676&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
            "title": "Kvartalsrapport Q2 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a8b28a04292205e718386a24bd65b425b",
            "date": "2025-08-26",
            "period": "2025-q2",
            "form_type": "interim-report",
            "report_key": "2025:q2",
            "filename": "Xbrane_Delarsrapport_Januari_Juni_2025.pdf",
            "text_chars": 49294,
            "sha256": "5ff496ee4d1781dd51924b3e53802d929b304b3523e29dad66af759ae0b29ee5",
            "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
            "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
            "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
                "chars": 49294
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q1",
        "period_label": "2025 Q1",
        "date": "2025-05-08",
        "title": "Kvartalsrapport Q1 2025",
        "original_title": "Xbrane Biopharma publicerar Delårsrapport januari-mars 2025",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bd530eb5ed65bc61b69ca3ae3b699c01e&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
            "title": "Kvartalsrapport Q1 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a8c392a9c26ea21acb0666e12bd29d58c",
            "date": "2025-05-08",
            "period": "2025-q1",
            "form_type": "interim-report",
            "report_key": "2025:q1",
            "filename": "Xbrane_Delarsrapport_Januari_Mars_2025.pdf",
            "text_chars": 44399,
            "sha256": "eebeffba94a890e55b83e3e31b6dae3ec4451ccb469e83db1504d24f6113b139",
            "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
            "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
            "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
                "chars": 44399
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:annual",
        "period_label": "2024 Årsredovisning",
        "date": "2025-03-31",
        "title": "Årsredovisning 2024",
        "original_title": "XBRANE BIOPHARMA PUBLICERAR ÅRS- OCH HÅLLBARHETSREDOVISNING FÖR 2024",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b58944d561bae385c0d3ce411b2591801&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2024,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2024",
            "title": "Årsredovisning 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a7eef0a3ebf43923dd5572e56af90417c",
            "date": "2025-03-31",
            "period": "2024-annual",
            "form_type": "annual-report",
            "report_key": "2024:annual",
            "filename": "Xbrane_Ars_Och_Hallbarhetsredovisning_2024.pdf",
            "text_chars": 325763,
            "sha256": "3f5b5f0e1147f37150907444d67397d2b022ad57ad5be6e7ce0829c99f5313c9",
            "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2024",
            "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2024",
            "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
                "chars": 178810
              },
              {
                "number": 2,
                "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
                "chars": 146951
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q4",
        "period_label": "2024 Q4",
        "date": "2025-02-20",
        "title": "Kvartalsrapport Q4 2024",
        "original_title": "Xbrane Biopharma publicerar bokslutskommuniké 2024",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=be76eea6c6fe702a12e453aa5b0995f24&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2024,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
            "title": "Kvartalsrapport Q4 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a4d584d783c99dfbd00656a582f145aed",
            "date": "2025-02-20",
            "period": "2024-q4",
            "form_type": "year-end-report",
            "report_key": "2024:q4",
            "filename": "Bokslutskommunike_2024_Xbrane_Biopharma.pdf",
            "text_chars": 66354,
            "sha256": "fabc4c3f648bfaae047c5f1794f2dc75e25771d6b0a6e15aa604843f962b1f70",
            "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
            "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
            "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
                "chars": 66354
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q3",
        "period_label": "2024 Q3",
        "date": "2024-10-24",
        "title": "Kvartalsrapport Q3 2024",
        "original_title": "Xbrane Biopharma publicerar delårsrapport för januari-september 2024",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b4b8d3dfe9277505314f56bf7e1d47c5e&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
            "title": "Kvartalsrapport Q3 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a8adcf2134633ef76ecaee3beb2b2afd3",
            "date": "2024-10-24",
            "period": "2024-q3",
            "form_type": "interim-report",
            "report_key": "2024:q3",
            "filename": "Xbrane_Delarsrapport_Januari_September_2024.pdf",
            "text_chars": 64031,
            "sha256": "fea7b56153d5e34d2498ca1265ed60625b390a87c8eaa9af74ea8fe81a6f0601",
            "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
            "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
            "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
                "chars": 64031
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q2",
        "period_label": "2024 Q2",
        "date": "2024-08-28",
        "title": "Kvartalsrapport Q2 2024",
        "original_title": "Xbrane Biopharma publicerar delårsrapport för januari-juni 2024",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b4bcb039a935da18c889d6f11d89b3da8&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
            "title": "Kvartalsrapport Q2 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/afcd1197113fc2b33e83865f022b318ab",
            "date": "2024-08-28",
            "period": "2024-q2",
            "form_type": "interim-report",
            "report_key": "2024:q2",
            "filename": "Xbrane_Delarsrapport_Januari_Juni_2024.pdf",
            "text_chars": 64019,
            "sha256": "13bfd4d1ca17750edb29ab5cf61d779d4e5b6e69751a3c38c3bd16f89e071875",
            "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
            "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
            "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
                "chars": 64019
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q1",
        "period_label": "2024 Q1",
        "date": "2024-05-16",
        "title": "Kvartalsrapport Q1 2024",
        "original_title": "Xbrane Biopharma publicerar delårsrapport för januari-mars 2024",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bbed386060026eb8c6afb9674019aee38&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024",
            "title": "Kvartalsrapport Q1 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/af09b23e96b28bf344d5899d50a74609a",
            "date": "2024-05-16",
            "period": "2024-q1",
            "form_type": "interim-report",
            "report_key": "2024:q1",
            "filename": "Xbrane_Delarsrapport_Januari_Mars_2024.pdf",
            "text_chars": 60276,
            "sha256": "f6d05051c23488cb563c691d05a2d6defeec9d034c1b584f3e6cd4eecfea6e12",
            "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
            "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
            "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html",
                "chars": 60276
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:annual",
        "period_label": "2023 Årsredovisning",
        "date": "2024-03-27",
        "title": "Årsredovisning 2023",
        "original_title": "XBRANE BIOPHARMA PUBLICERAR ÅRS- OCH HÅLLBARHETSREDOVISNING FÖR 2023",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b2fdf233b6feac2ec5383740bf8723aa3&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2023,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2023",
            "title": "Årsredovisning 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a6856e0b392caa7dc1b69afb9788317fd",
            "date": "2024-03-27",
            "period": "2023-annual",
            "form_type": "annual-report",
            "report_key": "2023:annual",
            "filename": "Ars_Och_Hallbarhetsredovisning_2023_Xbrane_Biopharma_AB.pdf",
            "text_chars": 350135,
            "sha256": "f2c82c155bbcd60f120feda5cb54d6785c0f8d90179e7d9d4bccd9c089063e8d",
            "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2023",
            "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2023",
            "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
                "chars": 178430
              },
              {
                "number": 2,
                "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2023/part-002.html",
                "chars": 171703
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q4",
        "period_label": "2023 Q4",
        "date": "2024-02-26",
        "title": "Kvartalsrapport Q4 2023",
        "original_title": "Xbrane Biopharma publicerar bokslutskommuniké 2023",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b154dada9da1be4d45f86322a1eeff6e7&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2023,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023",
            "title": "Kvartalsrapport Q4 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/aae2c3aebe98040e16efe5e5bf4419283",
            "date": "2024-02-26",
            "period": "2023-q4",
            "form_type": "year-end-report",
            "report_key": "2023:q4",
            "filename": "Xbrane_Bokslutskommunike_2023.pdf",
            "text_chars": 62036,
            "sha256": "3c0e145ce0ae8ac70264c1582c7127997cae57c2f4d7cc2236db75b7ba49f513",
            "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
            "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
            "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html",
                "chars": 62036
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q3",
        "period_label": "2023 Q3",
        "date": "2023-11-30",
        "title": "Kvartalsrapport Q3 2023",
        "original_title": "Xbrane Biopharma publicerar delårsrapport för januari - september 2023",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b2d386f2113484968b6f3832a3908579d&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2023,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
            "title": "Kvartalsrapport Q3 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/abc62f12149e6042fbd3d0330700058f6",
            "date": "2023-11-30",
            "period": "2023-q3",
            "form_type": "interim-report",
            "report_key": "2023:q3",
            "filename": "Xbrane_Delarsrapport_Janari_September_2023.pdf",
            "text_chars": 65523,
            "sha256": "b50e5ff5fcedba001dd13b6125e935ddba56e6a47f92c9aacc5eacf1abf426df",
            "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
            "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
            "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
                "chars": 65523
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q2",
        "period_label": "2023 Q2",
        "date": "2023-08-29",
        "title": "Kvartalsrapport Q2 2023",
        "original_title": "Xbrane Biopharma publicerar delårsrapport för januari - juni 2023",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bd15a1d16d5dd0155a56e66ae6120354a&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2023,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
            "title": "Kvartalsrapport Q2 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a69952714f15e9944fee6cea540351063",
            "date": "2023-08-29",
            "period": "2023-q2",
            "form_type": "interim-report",
            "report_key": "2023:q2",
            "filename": "Xbrane_Delarsrapport_Januari_Juni_2023.pdf",
            "text_chars": 67811,
            "sha256": "3bc9b51984690eb69acda822fed28ad70573c71682bb3fdf177c9f11c46934dd",
            "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
            "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
            "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
                "chars": 67811
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q1",
        "period_label": "2023 Q1",
        "date": "2023-05-31",
        "title": "Kvartalsrapport Q1 2023",
        "original_title": "Xbrane Biopharma publicerar delårsrapport för januari - mars 2023",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b36ceb6f7136d8f194bebbb0d3f2da048&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2023,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
            "title": "Kvartalsrapport Q1 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a7e48fde7152361f229b91537d0dfb244",
            "date": "2023-05-31",
            "period": "2023-q1",
            "form_type": "interim-report",
            "report_key": "2023:q1",
            "filename": "Xbrane_Delarsrapport_Januari_Mars_2023.pdf",
            "text_chars": 62648,
            "sha256": "cd9946c616fd15ef5bca6abaaf5a535bf592b856e067f4f2d356e83adff960d0",
            "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
            "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
            "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
                "chars": 62648
              }
            ]
          }
        ],
        "alternatives": []
      }
    ]
  },
  "report_count": 17,
  "nasdaq_report_count": 17,
  "mfn_fallback_count": 0,
  "sec_status": "skipped",
  "sec_count": 0,
  "fi_status": "retrieved",
  "fi_summary": {
    "company": "Xbrane Biopharma",
    "identity": {
      "issuer": "Hansa Biopharma AB",
      "lei": "549300LLEO25ZJJ3NT91",
      "source": "FI aggregerade blankningspositioner",
      "row_count": 13,
      "score": 50.0,
      "status": "resolved",
      "requested_company": "Xbrane Biopharma",
      "query": "Hansa Biopharma AB",
      "candidate_count": 345
    },
    "period": {
      "from": "2024-08-07",
      "to": "2026-08-07",
      "years": 2
    },
    "generated_at": "2026-08-07T08:44:50Z",
    "insider": {
      "transactions": 12,
      "all_export_rows": 12,
      "acquisitions": 6,
      "disposals": 6,
      "other": 0,
      "acquisition_value_sek": 22115723.56,
      "disposal_value_sek": 23620180.46,
      "characters": {
        "Avyttring": 6,
        "Förvärv": 6
      }
    },
    "short_selling": {
      "aggregate_percent": 4.21,
      "current_public_positions": 4,
      "historical_changes": 94,
      "current_position_sum_over_0_5": 2.68
    },
    "sources": {
      "insider_register": "https://www.fi.se/sv/vara-register/insynsregistret/",
      "short_register": "https://www.fi.se/sv/vara-register/blankningsregistret/"
    }
  },
  "warnings": [
    "MFN fallback: resolved_no_reports"
  ],
  "source_identity": {
    "nasdaq_reports": {
      "slug": "",
      "instrument_id": "TX1981696",
      "resolved_url": "https://www.nasdaq.com/european-market-activity/shares/xbrane?id=TX1981696"
    },
    "mfn": {
      "status": "resolved",
      "company_name": "Xbrane Biopharma",
      "expected_name": "Xbrane Biopharma",
      "match_score": 100.0,
      "slug": "xbrane-biopharma",
      "url": "https://mfn.se/all/a/xbrane-biopharma",
      "metadata": {
        "country": "Sverige",
        "list": "Small Cap Stockholm",
        "sector": "Hälsovård",
        "industry": "Bioteknik",
        "website": "https://xbrane.com/"
      },
      "ticker_candidates": [],
      "attempts": []
    },
    "sec": null,
    "nasdaq": {
      "instrument_id": "TX1981696",
      "asset_class": "SHARES",
      "isin": "SE0026598583",
      "symbol": "XBRANE",
      "company": "Xbrane Biopharma",
      "market": null,
      "last_sale_price": "SEK 10.00",
      "time_as_of": "2026-08-06"
    },
    "finansinspektionen": {
      "issuer": "Hansa Biopharma AB",
      "lei": "549300LLEO25ZJJ3NT91",
      "source": "FI aggregerade blankningspositioner",
      "row_count": 13,
      "score": 50.0,
      "status": "resolved",
      "requested_company": "Xbrane Biopharma",
      "query": "Hansa Biopharma AB",
      "candidate_count": 345
    }
  },
  "documents": [
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2026",
      "title": "Kvartalsrapport Q2 2026",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a8b00b947a5558a7cef2b0564a7b70cac",
      "date": "2026-07-17",
      "period": "2026-q2",
      "form_type": "interim-report",
      "report_key": "2026:q2",
      "filename": "Xbrane_Q2_2026_SVE_Final.pdf",
      "text_chars": 51755,
      "sha256": "7e3d3748b4c0f10fcbf22c4cb67faf9669e1483be41ef2ce36e7b6f44414b2d3",
      "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026",
      "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026",
      "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026/part-001.html",
          "chars": 51755
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
      "title": "Kvartalsrapport Q1 2026",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/acc297eb055190ad3b4286e211b143166",
      "date": "2026-05-05",
      "period": "2026-q1",
      "form_type": "interim-report",
      "report_key": "2026:q1",
      "filename": "Xbrnane_Q1_2026_SVE_Final.pdf",
      "text_chars": 45705,
      "sha256": "357f9101e71e4b40226b094761e2e48c3bf75479d1e9ee875639dd80adf3ccf2",
      "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
      "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
      "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
          "chars": 45705
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2025",
      "title": "Årsredovisning 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a9d342a40ad1e12dc500324a338e7209f",
      "date": "2026-03-31",
      "period": "2025-annual",
      "form_type": "annual-report",
      "report_key": "2025:annual",
      "filename": "Xbrane_AR_2025.pdf",
      "text_chars": 343429,
      "sha256": "fa1e0f6252dbc314c29334cc9f47339e138eda9fe1bbb323c6b6604635fdec75",
      "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2025",
      "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2025",
      "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
          "chars": 174293
        },
        {
          "number": 2,
          "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
          "chars": 169134
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
      "title": "Kvartalsrapport Q4 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a813f72aa1fe1d92f6a7849f53ce18fb2",
      "date": "2026-02-20",
      "period": "2025-q4",
      "form_type": "year-end-report",
      "report_key": "2025:q4",
      "filename": "Xbrane_Q4_2025_SV_Final.pdf",
      "text_chars": 52117,
      "sha256": "ccb9f087648165009e342257f1663f96082a2f50d5602cc0c5b9c88137520dd3",
      "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
      "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
      "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
          "chars": 52117
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
      "title": "Kvartalsrapport Q3 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ae3a7879bcb3b8d96fb5b9d491e2691eb",
      "date": "2025-10-24",
      "period": "2025-q3",
      "form_type": "interim-report",
      "report_key": "2025:q3",
      "filename": "Xbrane_Biopharma_Publicerar_Delarsrapport_Januari_September_2025.pdf",
      "text_chars": 53374,
      "sha256": "088aab35dd2d493f1f1dd6900780ae3ccef45d7ecea2df6a44e3e6f956d86223",
      "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
      "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
      "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
          "chars": 53374
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
      "title": "Kvartalsrapport Q2 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a8b28a04292205e718386a24bd65b425b",
      "date": "2025-08-26",
      "period": "2025-q2",
      "form_type": "interim-report",
      "report_key": "2025:q2",
      "filename": "Xbrane_Delarsrapport_Januari_Juni_2025.pdf",
      "text_chars": 49294,
      "sha256": "5ff496ee4d1781dd51924b3e53802d929b304b3523e29dad66af759ae0b29ee5",
      "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
      "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
      "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
          "chars": 49294
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
      "title": "Kvartalsrapport Q1 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a8c392a9c26ea21acb0666e12bd29d58c",
      "date": "2025-05-08",
      "period": "2025-q1",
      "form_type": "interim-report",
      "report_key": "2025:q1",
      "filename": "Xbrane_Delarsrapport_Januari_Mars_2025.pdf",
      "text_chars": 44399,
      "sha256": "eebeffba94a890e55b83e3e31b6dae3ec4451ccb469e83db1504d24f6113b139",
      "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
      "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
      "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
          "chars": 44399
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2024",
      "title": "Årsredovisning 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a7eef0a3ebf43923dd5572e56af90417c",
      "date": "2025-03-31",
      "period": "2024-annual",
      "form_type": "annual-report",
      "report_key": "2024:annual",
      "filename": "Xbrane_Ars_Och_Hallbarhetsredovisning_2024.pdf",
      "text_chars": 325763,
      "sha256": "3f5b5f0e1147f37150907444d67397d2b022ad57ad5be6e7ce0829c99f5313c9",
      "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2024",
      "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2024",
      "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
          "chars": 178810
        },
        {
          "number": 2,
          "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
          "chars": 146951
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
      "title": "Kvartalsrapport Q4 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a4d584d783c99dfbd00656a582f145aed",
      "date": "2025-02-20",
      "period": "2024-q4",
      "form_type": "year-end-report",
      "report_key": "2024:q4",
      "filename": "Bokslutskommunike_2024_Xbrane_Biopharma.pdf",
      "text_chars": 66354,
      "sha256": "fabc4c3f648bfaae047c5f1794f2dc75e25771d6b0a6e15aa604843f962b1f70",
      "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
      "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
      "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
          "chars": 66354
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
      "title": "Kvartalsrapport Q3 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a8adcf2134633ef76ecaee3beb2b2afd3",
      "date": "2024-10-24",
      "period": "2024-q3",
      "form_type": "interim-report",
      "report_key": "2024:q3",
      "filename": "Xbrane_Delarsrapport_Januari_September_2024.pdf",
      "text_chars": 64031,
      "sha256": "fea7b56153d5e34d2498ca1265ed60625b390a87c8eaa9af74ea8fe81a6f0601",
      "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
      "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
      "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
          "chars": 64031
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
      "title": "Kvartalsrapport Q2 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/afcd1197113fc2b33e83865f022b318ab",
      "date": "2024-08-28",
      "period": "2024-q2",
      "form_type": "interim-report",
      "report_key": "2024:q2",
      "filename": "Xbrane_Delarsrapport_Januari_Juni_2024.pdf",
      "text_chars": 64019,
      "sha256": "13bfd4d1ca17750edb29ab5cf61d779d4e5b6e69751a3c38c3bd16f89e071875",
      "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
      "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
      "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
          "chars": 64019
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024",
      "title": "Kvartalsrapport Q1 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/af09b23e96b28bf344d5899d50a74609a",
      "date": "2024-05-16",
      "period": "2024-q1",
      "form_type": "interim-report",
      "report_key": "2024:q1",
      "filename": "Xbrane_Delarsrapport_Januari_Mars_2024.pdf",
      "text_chars": 60276,
      "sha256": "f6d05051c23488cb563c691d05a2d6defeec9d034c1b584f3e6cd4eecfea6e12",
      "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
      "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
      "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html",
          "chars": 60276
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2023",
      "title": "Årsredovisning 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a6856e0b392caa7dc1b69afb9788317fd",
      "date": "2024-03-27",
      "period": "2023-annual",
      "form_type": "annual-report",
      "report_key": "2023:annual",
      "filename": "Ars_Och_Hallbarhetsredovisning_2023_Xbrane_Biopharma_AB.pdf",
      "text_chars": 350135,
      "sha256": "f2c82c155bbcd60f120feda5cb54d6785c0f8d90179e7d9d4bccd9c089063e8d",
      "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2023",
      "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2023",
      "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
          "chars": 178430
        },
        {
          "number": 2,
          "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2023/part-002.html",
          "chars": 171703
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023",
      "title": "Kvartalsrapport Q4 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/aae2c3aebe98040e16efe5e5bf4419283",
      "date": "2024-02-26",
      "period": "2023-q4",
      "form_type": "year-end-report",
      "report_key": "2023:q4",
      "filename": "Xbrane_Bokslutskommunike_2023.pdf",
      "text_chars": 62036,
      "sha256": "3c0e145ce0ae8ac70264c1582c7127997cae57c2f4d7cc2236db75b7ba49f513",
      "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
      "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
      "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html",
          "chars": 62036
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
      "title": "Kvartalsrapport Q3 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/abc62f12149e6042fbd3d0330700058f6",
      "date": "2023-11-30",
      "period": "2023-q3",
      "form_type": "interim-report",
      "report_key": "2023:q3",
      "filename": "Xbrane_Delarsrapport_Janari_September_2023.pdf",
      "text_chars": 65523,
      "sha256": "b50e5ff5fcedba001dd13b6125e935ddba56e6a47f92c9aacc5eacf1abf426df",
      "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
      "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
      "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
          "chars": 65523
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
      "title": "Kvartalsrapport Q2 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a69952714f15e9944fee6cea540351063",
      "date": "2023-08-29",
      "period": "2023-q2",
      "form_type": "interim-report",
      "report_key": "2023:q2",
      "filename": "Xbrane_Delarsrapport_Januari_Juni_2023.pdf",
      "text_chars": 67811,
      "sha256": "3bc9b51984690eb69acda822fed28ad70573c71682bb3fdf177c9f11c46934dd",
      "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
      "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
      "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
          "chars": 67811
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
      "title": "Kvartalsrapport Q1 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a7e48fde7152361f229b91537d0dfb244",
      "date": "2023-05-31",
      "period": "2023-q1",
      "form_type": "interim-report",
      "report_key": "2023:q1",
      "filename": "Xbrane_Delarsrapport_Januari_Mars_2023.pdf",
      "text_chars": 62648,
      "sha256": "cd9946c616fd15ef5bca6abaaf5a535bf592b856e067f4f2d356e83adff960d0",
      "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
      "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
      "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
          "chars": 62648
        }
      ]
    },
    {
      "doc_id": "mfn-mfn-bolagssida-och-bolagsmetadata",
      "title": "MFN bolagssida och bolagsmetadata",
      "source": "MFN",
      "source_class": "mfn",
      "source_url": "https://mfn.se/all/a/xbrane-biopharma",
      "date": null,
      "period": null,
      "form_type": "company-page",
      "report_key": null,
      "filename": "company.txt",
      "text_chars": 14274,
      "sha256": "75018dbea8a03a04cf8a7bd2996953ebb3288c2ff099ae360c6c7e14ff7ad666",
      "url": "/company/xbrane-biopharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
      "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
      "txt_url": "/company/xbrane-biopharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/xbrane-biopharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata/part-001.html",
          "chars": 14274
        }
      ]
    }
  ],
  "market_files": [
    {
      "label": "Nasdaq kurshistorik CSV",
      "url": "/company/xbrane-biopharma/market/history.csv",
      "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/market/history.csv"
    },
    {
      "label": "Nasdaq kurshistorik JSON",
      "url": "/company/xbrane-biopharma/market/history.json",
      "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/market/history.json"
    },
    {
      "label": "Nasdaq manifest JSON",
      "url": "/company/xbrane-biopharma/market/manifest.json",
      "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/market/manifest.json"
    },
    {
      "label": "Nasdaq instrumentidentitet JSON",
      "url": "/company/xbrane-biopharma/market/instrument.json",
      "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/market/instrument.json"
    },
    {
      "label": "MFN manifest JSON",
      "url": "/company/xbrane-biopharma/market/mfn-manifest.json",
      "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/market/mfn-manifest.json"
    },
    {
      "label": "Nasdaq rapportmanifest JSON",
      "url": "/company/xbrane-biopharma/market/nasdaq-reports-manifest.json",
      "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/market/nasdaq-reports-manifest.json"
    }
  ],
  "sec_facts": {
    "status": "missing",
    "metrics": []
  },
  "morningstar": {
    "configured": false,
    "status": "inte hämtad",
    "captured_at": null,
    "view_count": 0,
    "url": "/company/xbrane-biopharma/morningstar"
  },
  "finansinspektionen": {
    "available": true,
    "status": "retrieved",
    "url": "/company/xbrane-biopharma/finansinspektionen",
    "transaction_count": 12,
    "aggregate_short_percent": 4.21,
    "files": [
      {
        "filename": "summary.json",
        "label": "Sammanfattning JSON",
        "url": "summary.json"
      },
      {
        "filename": "insider-transactions.csv",
        "label": "Insynstransaktioner CSV",
        "url": "insider-transactions.csv"
      },
      {
        "filename": "insider-transactions.json",
        "label": "Insynstransaktioner JSON",
        "url": "insider-transactions.json"
      },
      {
        "filename": "short-current.json",
        "label": "Aktuella blankningspositioner JSON",
        "url": "short-current.json"
      },
      {
        "filename": "short-history.json",
        "label": "Historiska blankningspositioner JSON",
        "url": "short-history.json"
      },
      {
        "filename": "short-aggregate.json",
        "label": "Aggregerad blankning JSON",
        "url": "short-aggregate.json"
      },
      {
        "filename": "manifest.json",
        "label": "Hämtningsmanifest JSON",
        "url": "manifest.json"
      }
    ]
  },
  "llms_url": "/company/xbrane-biopharma/llms.txt",
  "json_url": "/company/xbrane-biopharma/company.json",
  "document_index_url": "/company/xbrane-biopharma/documents.json",
  "absolute_url": "https://spela.port0.org/company/xbrane-biopharma"
}